Regulatory status
Somatostatin is an unapproved research compound. There is no FDA-approved drug label, dosing information, or confirmed clinical indication associated with it in the data reviewed here.
What somatostatin is
Somatostatin is a peptide with the molecular formula C76H104N18O19S2 and a molecular weight of approximately 1,637.9 g/mol. Its structure includes a ring formed by a disulfide bond, a feature typical of this peptide family. The compound is catalogued under PubChem CID 16129706. No approved label describing its mechanism or drug class is available in this dataset.
Trial footprint
Somatostatin or compounds closely tied to its research appear across 575 registered clinical trials. Sampled studies span a range of contexts, including an open-label extension trial related to cystic kidney disease (NCT00771888), a completed trial comparing pegvisomant and octreotide in acromegaly (NCT00595140), and a completed trial evaluating [68 Ga]-DOTANOC PET/CT imaging in gastroenteropancreatic neuroendocrine tumors (NCT02608203). These examples illustrate the breadth of research interest rather than any established use, and they do not indicate that somatostatin itself is approved or effective for these purposes.